AIP
MNPR icon

Ameritas Investment Partners’s Monopar Therapeutics MNPR Stock Holding History

Ameritas Investment Partners’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.4K Hold
300
– – ﹤0.01% 2683
2025
Q4 		$19.6K Hold
300
– – ﹤0.01% 2650
2025
Q3 		$24.5K Sell
300
-115
-28% -$5.14K ﹤0.01% 2570
2025
Q2 		$14.8K Buy
+415
New +$15.1K ﹤0.01% 2801

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameritas Investment Partners's MNPR Position: Q1 2026 in Review

Ameritas Investment Partners held its Monopar Therapeutics (MNPR) position steady in Q1 2026 at 300 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

Ameritas Investment Partners first reported a position in MNPR in Q2 2025 and has held it in 4 quarters since. The position peaked at $24.5K in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Ameritas Investment Partners held 300 shares of Monopar Therapeutics worth $16.4K as of Q1 2026.
  • Ameritas Investment Partners left its Monopar Therapeutics share count unchanged in Q1 2026.
  • Monopar Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2683 holding.
  • Ameritas Investment Partners first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ameritas Investment Partners's Monopar Therapeutics position peaked at $24.5K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.